Clicky

TabletWise.com
    Pharmacy Website
    Clinic Website
     

    Intelligence » Psoriasis » Last Week

    Subscribe to get latest posts via email or subscribe to a RSS feed.

    FDA declines to approve Valeant's plaque psoriasis lotion

    Monday, June 18, 2018 -- (Reuters) - Valeant Pharmaceuticals International Inc's plaque psoriasis treatment did not get approval from U.S. health regulators, a setback for the company which had high hopes for the lotion.

    Adalimumab reduces inflammation markers in patients with psoriasis

    Monday, June 18, 2018 -- Patients with psoriasis who were treated with adalimumab had a reduction in key markers of inflammation such as glycoprotein acetylation compared with those treated with phototherapy, according to a study published in Circulation: Cardiovascular Imaging.“[Tumor necrosis factor, interleukin-6, C-reactive protein and glycoprotein acetylation] are known to predict future cardiovascular events, and thus reducing these markers of inflammation suggests a cardioprotective effect,” Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology, vice chair of clinical research,

    US FDA rejects Valeant’s Duobrii for plaque psoriasis

    Tuesday, June 19, 2018 -- The US FDA has rejected Valeant Pharmaceutical Internationalâs investigational topical treatment for plaque psoriasis, Duobrii.

    Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

    Wednesday, June 20, 2018 -- A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis every year in the United States, affecting 2.2% of the population.

    Setback For Valeant Psoriasis Treatment Over Pharmacokinetic Data

    Wednesday, June 20, 2018 -- NewsThe FDA has issued a Complete Response Letter to Valeant for its Duobrii lotion. The agency did not specify any deficiencies related to the clinical efficacy or safety, but noted questions regarding pharmacokinetic data.Contributed Author: Valeant Pharmaceuticals International, Inc.Topics: Regulatory